References
- World Health Organization. Anti-tuberculosis drug resis-tance in the world. WHO/TB/97/229.
- Corbett EL, Watt CJ, Neff Walker N et al. The growing burden of Tuberculosis. Global trends and interactions with the HIV Epidemic. Arch intern Med 2003; 163: 1009–1021.
- Tuberculosis Research Centre, Indian Council of Medical Research, Chennai. Shortening short course chemotherapy: A randomized clinical trial for treatment of smear positive pul-monary tuberculosis with regimens using ofloxacin in the intensive phase. Indian J Tuberc2002; 49: 27–38.
- Tsukamura, M, Nakamura E, Yoshif S, Amano H. Therapeutic effect of new antibacterial substance, ofloxacin (DL-8280) on pulmonary tuberculosis. Am Rev Respir Dis 1985; 131: 559–64.
- Tomioka HL, Saito H, Sato K. Comparative antimy-cobacterial activities of the newly synthesized quinolone AM1155, sparfloxacin and ofloxacin. Antimicrob Agents Chemother 1993; 37: 1259-1263.
- Lu T, Zhao X, Li X, et al. Enhancement of fluoro-quinolones activity by C-8 halogen and methoxy moieties: Action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase- topoisomerase IV double mutant of Staphylococcus aureus. Antimicrob Agents Chemother 2001; 45: 2703–2709.
- Dong Y, Xu C, Zhao X, Domagala J, Drilica K. Fluoroquinolone action against Mycobacteria: Effects of C-8 substituents on growth, survival, and resistance. Antimicrob Agents Chemother 1998; 42: 2978-2984.
- Sulochana S, Venkataraman P, Paramasivan CN. Evaluation of various methods of susceptibility to ofloxacin in strains of Mycobacterium tuberculosis. Ind J Med Res 1999; 110: 186–189.
- Canetti G, Fox W, Khomenko A et al. Advances in techniques of testing mycobacterial drug sensitivity and the use of sensitivity tests in tuberculosis control programmes. Bull WHO 1969; 41: 21–43.
- Jensen, KA. Towards a standardization of laboratory methods. Second report of the Sub-Committee of Laboratory Methods of the International Union Against tuberculosis. Bull Int Union Tuberc 1955; 25 (1-2): 89–104.
- Cohn, ML, Waggoner RF, McClatchy JK. The 7H11 medium for the cultivation of Mycobacteria. Am Rev Respir Dis 1968; 98: 295–296.
- Sirgel FA, Donald PR, Odhaimbo J et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 2000; 45: 859–870.
- Kent PT, Kubica GP. Antituberculosis Chemotherapy and drug susceptibility testing in Public Health Mycobacteriology. 1985: In: A guide for level III laboratory. Centers for Disease Control, Atlanta, Ga. 159-84.
- NCCLS. Susceptibility testing of Mycobacteria, Nocardia and Other Aerobic Actinomycetes. NCCLS docu-ment 2003; M24-A 23: No.18, 1-71.
- Mohanty KC, Dhamgaye TM. Controlled clinical trial of ciprofloxacin in short term chemotherapy for pulmonary tuberculosis. Chest. 1993; 104: 1194–8.
- Kohno S, Koga H, Kasu M, Maesaki S, Hara K. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest 1992; 102: 1815–1818.
- U.S. Pharmacist. Review of New Drug. U.S. Pharmacist Continuing Education. Oct 2002; ACPE Program No.430-000-00-030-H01.
- Alvirez-Freites EJ, Carter JL, Cynamon MH. In vitro and In vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2002; 46: 1022–1025.
- Yoshimatsu T, Nuermberger EL, Tyagi S, Chasson R, Bishai WR, Grosset J. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob. Agents Chemother 2002 ; 46: 1875–1879.
- Nuermberger EL, Yoshimatsu T, Tyagi S et al. Moxifloxacin-containing regimen greatly reduces time to cul-ture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004; 169: 421–426.
- Miyazaki E, Miyazaki M, Chen JM, Chaisson RE, Bishai WR. Moxifloxacin (BAY 12-8039), a new 8 methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999; 43: 85–89.
- Fattorini L, Tan D, Lona E, et al. Activities of moxi-floxacin alone and in combination with other antimicrobial agents against multidrug resistant Mycobacterium tuberculo-sis infection in BALB/c mice. Antimicrob Agents Chemother 2003; 47: 360–362.
- Hu Y, Coates ARM, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003:47: 653–657.
- Ruiz-Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first line anti tuberculosis drugs. Antimicrob Agents Chemother 2000; 44: 2567–2568.